Reports of Bartter syndrome in premature neonates are rare. We describe the presentation and clinical course of a neonate born at 25.6 weeks estimated gestational age with polyuria, hyponatremia, hypokalemia and hypercalciuria ,who was diagnosed with neonatal Bartter syndrome. The evaluation, diagnosis and management of neonatal Bartter syndrome in this premature neonate are discussed.
INTRODUCTION
Bartter syndrome is a rare congenital renal tubular disorder causing an imbalance of potassium, sodium, chloride and calcium. It is classified into five types: (1) neonatal (Types I and II), (2) classic (Type III) and (3) neonatal with sensorineural deafness (Types IV and V). 1, 2 Although the prevalence of Bartter syndrome in the United States is unknown, certain populations have incidences of 1.2 to 1.7/100 000. 3 Neonatal Bartter syndrome is characterized by early onset, maternal polyhydramnios without apparent fetal or placental abnormalities. 4 Affected neonates have postnatal polyuria, loss of electrolytes in the urine, hypercalciuria, and subsequently develop nephrocalcinosis. We present a case of Bartter syndrome in an infant delivered at 25.6 weeks estimated gestational age (EGA).
CASE
The mother was a healthy 27 year old G5P4004 with unremarkable prenatal labs and no history of alcohol or illegal drug use. The parents were nonconsanguineous. She presented to an outside hospital with abdominal pain and nausea and was noted to have significant polyhydramnios at 25.4 weeks EGA. She received indomethacin for the polyhydramnios and was transferred for perinatology consultation.
The initial amniotic fluid index (AFI) was 48 cm (normal 4 to 18 cm) 5 , and after 2 l of fluid were removed, the AFI decreased to 27 cm. However, within 24 h it again increased to 35 cm. Spontaneous rupture of membranes occurred, and the infant was delivered 36 h later by emergent Cesarean section secondary to placental abruption.
The infant weighed 920 g and had Apgar scores of 7 and 8 at 1 and 5 min, respectively. She was intubated and received Survanta before being transferred to the Neonatal Intensive Care Unit (NICU). In the first 24 h, she was hemodynamically stable and was extubated to bubble continuous positive airway pressure. However, her urine output was noted to be 47.6 ml kg
, and increased to 9.7 ml kg À 1 h À 1 in the subsequent 24 to 48 h. Urine specific gravity and urine osmolality were 1.004 and 306, respectively. Electrolytes in the first 96 h are shown in the Table 1 . Aggressive fluid and electrolyte replacement were performed every 6 h. On day of life (DOL) 2, her weight decreased to 820 g despite fluid replacement and on DOL 3 of life, it had decreased further to 670 g.
Nephrology phone consultation was obtained on DOL 2, and recommendations were for continued replacement of urine output and supplementation of electrolyte deficits. On DOL 3 the patient was transferred for evaluation for possible Bartter syndrome.
The infant's urine output continued to be B10 ml kg À 1 h À 1 . On DOL 4 the urine calcium:creatinine ratio was 3 (normal o0.8). On DOL 5, a plasma renin activity was 208,624 ng dl
(reference range, 200 to 3500 ng dl À 1 h À 1 ) and aldosterone was 260 pg ml À 1 (reference range, 574 ± 54.5 pg ml À 1 ). On DOL 15, the infant was started on indomethacin at 0.1 mg kg À 1 IV q 12 h, and on DOL 21, the dose was increased to 0.15 mg per kg IV q 12 h. After initially being NPO during the indomethacin treatment, the infant resumed feedings, and her indomethacin was changed to oral. However, the next day, she developed signs of sepsis, was made NPO, and underwent antibiotic treatment. No abdominal concerns developed during this time.
When she achieved full feedings, the infant was changed to oral indomethacin at 0.54 mg per kg q 12 h. On DOL 35, urine replacement was no longer necessary. Genetic evaluation revealed a compound heterozygous mutational defect in the sequencing of the SLC12A1 gene, confirming neonatal Bartter syndrome, Type I. The nucleotide changes were c.1315G4A and c.695C4T.
During the hospitalization, the patient developed an Enterococcus fecalis urinary tract infection, and a renal ultrasound revealed bilateral pelvocaliectasis. A follow up renal ultrasound continued to show persistent pelvocaliectasis and echogenic foci consistent with nephrocalcinosis.
During the hospital stay she exhibited failure to gain weight despite 150 to 160 ml kg À 1 per day. The caloric density of her feedings was increased to 28 cal per oz, and then was able to be stepped down to 22 cal per oz before discharge. The infant remained in the NICU for 144 days when she was discharged to home on supplemental potassium chloride and indomethacin.
1 DISCUSSION 1n 1962, Frederic Bartter wrote the seminal paper describing two patients with hypokalemic metabolic alkalosis, hyperaldosteronism, normal blood pressure, decreased pressor responsiveness to angiotensin II infusion, and hyperplasia of the juxtaglomerular apparatus. 6 Bartter syndrome represents a set of closely related, autosomal recessive renal tubular disorders consisting of four neonatal variants (Type I, II, IV and V) with Types IV and V being associated with neonatal deafness. Types I-II have severe antenatal symptoms. 4 Unexplained polyhydramnios between 24 to 30 weeks of gestation is characteristic of fetuses with Bartter syndrome. 7 Prenatal diagnosis can be made by the high chloride content of the amniotic fluid, 8 and the mother can be managed with indomethacin (1 mg kg
). 7 Indomethacin inhibits prostaglandin synthetase, decreasing renal salt wasting, and reducing fetal urine output. As indomethacin may cause premature closure of the fetal ductus arteriosus, monitoring of the fetus during maternal treatment is critical. Despite indomethacin, some patients may require therapeutic amniocentesis or a combination of indomethacin and amniocentesis in order to continue the pregnancy to a more mature gestation.
Neonates suspect for Bartter syndrome should be monitored closely for urine output, hydration status, weight loss and electrolyte balance. The characteristic electrolyte abnormalities include hypokalemia and metabolic alkalosis. Urine electrolytes will show elevated sodium, chloride, calcium, with urinary potassium increasing after 1 to 3 weeks. Other laboratory findings include elevated prostaglandin levels in blood and urine. Serum aldosterone levels and plasma renin activity are also elevated due to activation of the renin-aldosterone axis.
The initial management of these patients includes provision of sufficient fluids and electrolytes to balance hydration and electrolyte status. Large amounts of sodium chloride supplementation are necessary. Potassium supplementation is usually needed by 2 to 3 weeks of age. Prostaglandin synthetase inhibitors are usually required, and indomethacin is the the most commonly used. It decreases the salt wasting, metabolic alkalosis and can cause a reduction of the glomerular filtration rate. A dose of 1 to 5 mg per kg per day is usually recommended. 4, 9 Observation for potential side effects including spontaneous intestinal perforation is critical, particularly in the premature neonate. 4, 9 The prognosis of neonates with antenatal Bartter syndrome can be satisfactory. 4, 10 Long-term outcome including mental development and puberty is usually normal. 4, 9, 10 Growth retardation and failure to thrive occur in nearly all patients with Bartter syndrome. Developmental delay has been described. Some patients have spontaneous recovery following a period of treatment, 11 while others may require renal transplantation, especially those with Type IV. Chronic renal failure was noted to occur in some children with Bartter syndrome. 4, 12 In conclusion, early recognition of maternal polyhydramnios can facilitate identification of neonates with Bartter syndrome, and may permit the pregnancy to advance to a more mature gestational age. Most cases of Bartter syndrome have been reported at 30 weeks EGA or later. 12 We present the case of an extremely premature neonate, and review the unique problems with fluid management, nutritional needs, and risks associated with indomethacin use in this population. Long-term outcome in more premature neonates may be more a reflection of their gestational age rather than the underlying neonatal Bartter syndrome. 
